Bone Metastases from Prostate Cancer: From Symptom Control to Pain Palliation

Caraceni, Augusto; Zecca, Ernesto; Formaglio, Fabio; Ricchini, Francesca

doi:10.1007/978-3-319-42327-2_19

Cited by 2 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study of cancer-related genes, which can be used as markers to predict the stages of a variety of cancers, and especially the aggressiveness of prostate cancer, is of clinical interest to many researchers (1,2). Research has confirmed that prostate cancer is the second most common cancer and the fifth leading cause of cancer death in men (3,4). According to the reports of the United States, one in six men suffers from prostate cancer during his lifetime, and more than 200,000 people are diagnosed with the disease each year.…”

Section: Introductionmentioning

confidence: 99%

Molecular Expression of Some Oncogenes and Predisposing Behaviors Contributing to the Aggressiveness of Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

Background: Prostate cancer is the second most common cancer in men in Iran. It can be treated in the early stages of the disease; therefore, early diagnosis can be lifesaving. The aim of this study was to investigate the molecular expression of some oncogenes and predisposing behaviors contributing to the aggressiveness of prostate cancer. Methods: In this case-control study, prostate cancer specimens were collected from both patients and healthy volunteers. Several factors such as age, family history, smoking, and stage of the disease, were investigated based on the criteria of this study. Real-time PCR was used to measure the expression of four oncogenes. Statistical analysis of our data was carried out using SPSS software version 22. Results: The X 2 test showed that there was a difference in the incidence of prostate cancer in different age groups (X 2 = 9.30; p= 0.026). Although data analysis by the X 2 test showed that family history had a significant effect on prostate cancer (X 2 = 14.43; p= 0.001), smoking did not show a significant effect on the incidence of this disorder (X 2 = 4.67; p= 0.097). The T2N1M0 stage is the most common form of prostate cancer in patients with family history of prostate cancer and the habit of smoking. Also, the expression of KRAS1P, GLB1L2, SChLAP1 and PACSIN3 oncogenes reduced in prostate cancer samples compared to the control group. Conclusions: Overall, functional interpretation of gene expression in the prostate tissue can affect tumor progression. Yet, further practical studies are required to reveal the accurate underlying mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular Expression of Some Oncogenes and Predisposing Behaviors Contributing to the Aggressiveness of Prostate Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Pharmacological management of cancerinduced bone pain involves the use of analgesic such as nonsteroidal anti-inflammatory drugs (NSAID) in combination with another treatment such as chemotherapy and radiotherapy. The commonly-used NSAIDs are meloxicam and sodium diclofenac [6].…”

Section: Introduction mentioning

confidence: 99%

Pharmacokinetics Interaction of Non-Steroid Anti Inflammatory Drugs to <sup>99m</sup>Tc-MDP Radiopharmaceuticals for Bone Imaging and Its Biodistribution

et al. 2018

View full text Add to dashboard Cite

Tc-MDP Meloxicam Sodium diclofenac 99m Tc-MDP has been developed as a radiopharmaceutical for bone imaging in nuclear medicine. A drug therapy can alter the pharmacokinetic profiles and biodistribution patterns of radiopharmaceuticals. To achieve an optimum diagnostic outcome, this research focused on pharmacokinetics interaction between two kinds of nonsteroidal anti-inflammatory drugs (NSAID) drugs, meloxicam and sodium diclofenac with 99m Tc-MDP using mice (Mus musculus). There were five groups of animal model and each group consists of three mice except for group II and III which consists of six mice. The groups were classified as untreated mice (I), mice treated with meloxicam for 3 days (II), treated with sodium diclofenac for 3 days (III), treated with meloxicam once or at onset (IV), and mice with sodium diclofenac once or at onset (V). Pharmacokinetics interaction and biodistribution test were conducted by injecting 100 µCi/100 µL 99m Tc-MDP intravenously. Blood samples were withdrawn from each mouse which were then weighted and counted using single channel analyzer. The %ID/g of 99m Tc-MDP in blood of untreated mice (I), mice treated with meloxicam (II) and sodium diclofenac (III) 5 minutes post injection were 3.71, 8.96 and 9.15 % respectively, then decrease to 0.12, 0.01, and 0.01 %, respectively, 24 hours post injection. The results of T-test showed there were no significant differences in distribution of 99m Tc-MDP in untreated mice (I) and in treated mice either with meloxicam (II) or sodium diclofenac (III). However, there was significant difference in elimination of 99m Tc-MDP in untreated mice (I) and in treated mice either with meloxicam (II) or sodium diclofenac (III). The bone uptakes of 99m Tc-MDP were 9.03 ± 0.41, 3.52 + 0.52, 3.62 + 0.45, 8.44 + 1.39, and 8.09 ± 0.86 % in group I, II, III, IV, and V, respectively. T-test showed there were significant differences in bone uptake of 99m Tc-MDP in mice with previously treated with meloxicam and sodium diclofenac for 3 days. From these result, it can be concluded that an administration of meloxicam and sodium diclofenac could accelerate elimination half-life that cause low uptake of 99m Tc-MDP radiopharmaceutical on the bone as the primary target. Therefore, it is necessary to follow up using image study to determine the significance of the effects on image quality.

show abstract

Bone Metastases from Prostate Cancer: From Symptom Control to Pain Palliation

Cited by 2 publications

References 80 publications

Molecular Expression of Some Oncogenes and Predisposing Behaviors Contributing to the Aggressiveness of Prostate Cancer

Molecular Expression of Some Oncogenes and Predisposing Behaviors Contributing to the Aggressiveness of Prostate Cancer

Pharmacokinetics Interaction of Non-Steroid Anti Inflammatory Drugs to <sup>99m</sup>Tc-MDP Radiopharmaceuticals for Bone Imaging and Its Biodistribution

Contact Info

Product

Resources

About